-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CLS-12311 in Relapsing Remitting Multiple Sclerosis (RRMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CLS-12311 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details: CLS-12311 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CLS-12311 in Secondary Progressive Multiple Sclerosis (SPMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CLS-12311 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details: CLS-12311 is under development for the treatment...
-
Product Insights
CreightonU – CL Werner Center For Health Sciences Education – Nebraska
Equip yourself with the essential tools needed to make informed and profitable decisions with our CreightonU - CL Werner Center For Health Sciences Education - Nebraska report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TP-05 in Malaria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TP-05 in Malaria Drug Details:Lotilaner is under development for the prevention of lyme disease and community...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TP-05 in Lyme Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TP-05 in Lyme Disease Drug Details:Lotilaner is under development for the prevention of lyme disease and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lotilaner in Blepharitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lotilaner in BlepharitisDrug Details:Lotilaner is under development for the treatment of demodex blepharitis and meibomian gland...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-101 in Neuropathic Pain (Neuralgia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AV-101 in Neuropathic Pain (Neuralgia) Drug Details:AV-101 is under development for the treatment of neuropathic pain,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-101 in Major Depressive Disorder
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AV-101 in Major Depressive DisorderDrug Details:AV-101 is under development for the treatment of neuropathic pain, dyskinesia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-101 in Drug-Induced Dyskinesia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AV-101 in Drug-Induced DyskinesiaDrug Details:AV-101 is under development for the treatment of neuropathic pain, dyskinesia associated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lotilaner in Meibomian Blepharitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lotilaner in Meibomian Blepharitis Drug Details: Lotilaner (Xdemvy) belongs to a member of isoxazoline class...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Furosemide in Congestive Heart Failure (Heart Failure)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Furosemide in Congestive Heart Failure (Heart Failure) Drug Details:Furosemide (Furoscix) is a sulfamoylanthranilic acid derivative, acts...
-
Product Insights
West Cameron 73 Field, United States
West Cameron 73 upstream field is located in Central Planning Area, United States. The upstream field is owned by CL&F Resources LP (6.83%); McMoRan Oil & Gas LLC (70%); Walter Oil & Gas Corp (23.17%). It is operated by Walter Oil & Gas Corp. The project started its operations in 2003. West Cameron 73 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as...
-
Product Insights
Barataria Field, United States
Barataria upstream field is located in Central Planning Area, United States. The upstream field is owned by CL&F Offshore LLC (7%); Houston Energy Deepwater Ventures IX LLC (3%); Kosmos Energy Gulf of Mexico Operations LLC (22.50%); Red Willow Offshore LLC (19.80%); Ridgewood Barataria LLC (23.85%); Talos Exploration LLC (23.85%). It is operated by Kosmos Energy Gulf of Mexico Operations LLC . The project started its operations in 2017. Barataria Upstream Field profile includes core details such as name, resource type,...
-
Product Insights
Khaleesi Field, United States
Khaleesi upstream field is located in Central Planning Area, United States. The upstream field is owned by CL&F Offshore LLC (4%); HEDV Khaleesi LLC (5.50%); ILX Prospect Khaleesi LLC (11.33%); Murphy Exploration & Production Co (34%); Red Willow Offshore LLC (22.50%); Ridgewood Khaleesi LLC (17%); Ridgewood Rialto Holdings LLC (5.67%). It is operated by Murphy Exploration & Production Co. The project started its operations in 2022. Khaleesi Upstream Field profile includes core details such as name, resource type, asset status,...
-
Product Insights
Claiborne Field, United States
Claiborne upstream field is located in Central Planning Area, United States. The upstream field is owned by Beacon Growthco Operating Co LLC (0.32%); Beacon Offshore Energy Operating LLC (23.07%); CL&F Offshore LLC (9%); Red Willow Offshore LLC (9%); Ridgewood Claiborne LLC (25.25%); Ridgewood Rattlesnake LLC (8.11%); Talos Exploration LLC (25.25%). It is operated by Beacon Growthco Operating Co LLC. The project started its operations in 2018. Claiborne Upstream Field profile includes core details such as name, resource type, asset status,...
-
Product Insights
Mormont Field, United States
Mormont upstream field is located in Central Planning Area, United States. The upstream field is owned by CL&F Offshore LLC (4%); HEDV Mormont LLC (5.50%); ILX Prospect Mormont LLC (11.33%); Murphy Exploration & Production Co (34%); Red Willow Offshore LLC (22.50%); Ridgewood Mormont LLC (17%); Ridgewood Rialto Holdings LLC (5.67%). It is operated by Murphy Exploration & Production Co. The project started its operations in 2022. Mormont Upstream Field profile includes core details such as name, resource type, asset status,...
-
Product Insights
Ship Shoal 170 Field, United States
Ship Shoal 170 upstream field is located in Central Planning Area, United States. The upstream field is owned by BDX Group LLC (26.73%); Bois D' Arc Exploration Llc (0.27%); CL&F Resources LP (48%); Tenkay Resources Inc (25%). It is operated by Bois D' Arc Exploration Llc. The project started its operations in 2014. Ship Shoal 170 Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur),...
-
Product Insights
Praline Field, United States
Praline upstream field is located in Central Planning Area, United States. The upstream field is owned by CL&F Offshore LLC (10%); Houston Energy Deepwater Ventures XII LLC (10%); ILX Prospect Praline LLC (21.38%); LLOG Exploration Offshore LLC (27.25%); Red Willow Offshore LLC (10%); Ridgewood Praline LLC (21.37%). It is operated by LLOG Exploration Offshore LLC. The project started its operations in 2020. Praline Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity...
-
Product Insights
Gladden Field, United States
Gladden upstream field is located in Central Planning Area, United States. The upstream field is owned by Arena Exploration (12.50%); CL&F Resources LP (10%); Kosmos Energy Gulf of Mexico Operations LLC (20%); W&T Offshore Inc (57.50%). It is operated by W&T Offshore Inc. The project started its operations in 2011. Gladden Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key...
-
Product Insights
South Marsh Island 257 Field, United States
South Marsh Island 257 upstream field is located in Central Planning Area, United States. The upstream field is owned by CL&F Resources LP (33.75%); CNOOC Petroleum Offshore USA Inc (31.05%); He&D Offshore LP (10%); Helis Oil & Gas Co LLC (22.50%); Houston Energy LP (2.70%). It is operated by Helis Oil & Gas Co LLC. The project started its operations in 1978. South Marsh Island 257 Upstream Field profile includes core details such as name, resource type, asset status, stage,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.